Humanized pertussis antibodies and uses thereof
US-9512204-B2 · Dec 6, 2016 · US
Humanized pertussis antibodies and used thereof
US10526400B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10526400-B2 |
| Application number | US-201816016890-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 25, 2018 |
| Priority date | Mar 31, 2014 |
| Publication date | Jan 7, 2020 |
| Grant date | Jan 7, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a patient infected with Bordetella pertussis , comprising administering to the patient an effective amount of a humanized 11 E6 antibody comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein the immunoglobulin heavy chain variable region comprises an amino acid sequence SEQ ID NO: 18, and the immunoglobulin light chain variable region comprises an amino acid sequence SEQ ID NO: 23. 2. The method of claim 1 , wherein the humanized 11E6 antibody binds the pertussis toxin protein with a KD of 12 nM or lower. 3. The method of claim 1 , further comprising administering an effective amount of a humanized 1 B7 antibody, wherein the humanized 1B7 antibody comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein the immunoglobulin heavy chain variable region comprises an amino acid sequence SEQ ID NO: 3, and the immunoglobulin light chain variable region comprises an amino acid sequence SEQ ID NO: 11. 4. The method of claim 3 , wherein the humanized 1B7 antibody binds to the pertussis toxin protein with a KD of 3 nM or lower.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antibacterial agents · CPC title
Antitussive agents · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10526400B2 cover?
- The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
- Who is the assignee on this patent?
- Univ Texas, Synthetic Biologics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1225. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).